RU2001101445A - APPLICATION OF PEG-INTERFERON-ALPHA (PEG-IFN-ALPHA) AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C - Google Patents

APPLICATION OF PEG-INTERFERON-ALPHA (PEG-IFN-ALPHA) AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C

Info

Publication number
RU2001101445A
RU2001101445A RU2001101445/14A RU2001101445A RU2001101445A RU 2001101445 A RU2001101445 A RU 2001101445A RU 2001101445/14 A RU2001101445/14 A RU 2001101445/14A RU 2001101445 A RU2001101445 A RU 2001101445A RU 2001101445 A RU2001101445 A RU 2001101445A
Authority
RU
Russia
Prior art keywords
peg
ifn
ribavirin
alpha
conjugate
Prior art date
Application number
RU2001101445/14A
Other languages
Russian (ru)
Inventor
ЗАМ Фредерик
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of RU2001101445A publication Critical patent/RU2001101445A/en

Links

Claims (1)

1. Применение конъюгатов ПЭГ-IFN-α в сочетании с рибавирином для приготовления лекарственного средства, предназначенного для лечения заболеваний хроническим гепатитом С.1. The use of conjugates of PEG-IFN-α in combination with ribavirin for the preparation of a medicinal product intended for the treatment of diseases of chronic hepatitis C. 2. Применение по п. 1, где количество конъюгата ПЭГ-IFN-α составляет приблизительно 33 - 540 мкг/неделю. 2. The use according to claim 1, wherein the amount of the PEG-IFN-α conjugate is approximately 33 to 540 μg / week. 3. Применение по п. 1, где количество рибавирина составляет 400 - 1200 мг/день. 3. The use according to claim 1, where the amount of ribavirin is 400-1200 mg / day. 4. Применение по пп. 1-3, где конъюгат ПЭГ-IFN-α представляет собой конъюгат ПГЭ-IFN-α2A формулы
Figure 00000001

где R и R' обозначают метил, Х обозначает NH и n и n' каждый по отдельности или оба равны 420 или 520.4. The use of paragraphs. 1-3, where the conjugate PEG-IFN-α is a conjugate PGE-IFN-α2A formula
Figure 00000001

where R and R 'denote methyl, X denotes NH and n and n' each individually or both are 420 or 520. 5. Способ лечения заболевания хроническим гепатитом С, предусматривающий введение конъюгата ПЭГ-IFN-α в сочетании с рибавирином в количествах, эффективных для лечения хронического гепатита С. 5. A method of treating chronic hepatitis C disease, comprising administering a PEG-IFN-α conjugate in combination with ribavirin in amounts effective for treating chronic hepatitis C. 6. Способ по п. 5, где количество конъюгата ПЭГ-IFN-α, вводимого согласно указанному способу, составляет приблизительно 33-540 мкг/неделю. 6. The method of claim 5, wherein the amount of the PEG-IFN-α conjugate administered according to the indicated method is approximately 33-540 μg / week. 7. Способ по п. 5, где количество рибавирина, вводимого согласно указанному способу, составляет 400-1200 мг/день. 7. A method according to claim 5, where the number of ribavirin, administered according to the specified method, is 400-1200 mg / day. 8. Способ по любому из пп. 5-7, где вводимый конъюгат ПЭГ-IFN-α представляет собой ПЭГ-IFN-α2A.
9. Применение конъюгата ПЭГ-IFN-α и рибавирина для лечения заболеваний хроническим гепатитом С.8. A method according to any one of claims. 5-7, where the injected conjugate of PEG-IFN-α is a PEG-IFN-α2A.
9. The use of the conjugate PEG-IFN-α and ribavirin for the treatment of diseases of chronic hepatitis C. 10. Изобретение как оно описано выше. 10. The invention as described above.
RU2001101445/14A 1998-06-08 1999-05-29 APPLICATION OF PEG-INTERFERON-ALPHA (PEG-IFN-ALPHA) AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C RU2001101445A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98110433.4 1998-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2003119460/14A Division RU2271217C2 (en) 1998-06-08 1999-05-29 USING POLYETHYLENE GLYCOL-INTERFERON-α (PEG-IFN-α) AND RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C

Publications (1)

Publication Number Publication Date
RU2001101445A true RU2001101445A (en) 2002-11-20

Family

ID=

Similar Documents

Publication Publication Date Title
RU2003119460A (en) APPLICATION OF PEG-INTERFERON-A (PEG-INF-A) AND RIBAVIRIN FOR TREATMENT OF CHRONIC HEPATITIS C
BR9911076A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C
HUP0300421A2 (en) Method of treatment using ligand-immunogen conjugates
ES2295609T3 (en) TIADIAZOLILPIPERAZINA DERIVATIVES USEFUL TO TREAT OR PREVENT A PAIN.
BR0114636A (en) Pegylated interferon-alpha / ribavirin hcv combination therapy
CY1105707T1 (en) COMBINATIONS OF FORMOTEROL AND A TRIOTROP SALT
YU13695A (en) Application of 2-phenyl-3-aroylbenzothiophene and pharmaceutical formulations thereof
RU95101385A (en) Products containing g-csf and tnf-binding protein
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
KR950016760A (en) Hemorrhoids Treatment
TR200200401T2 (en) Mycophenolate mofetil with PEG-IFN-a
JP2003514025A5 (en)
RU96103685A (en) 1,2,5-TIADIAZOLIC DERIVATIVES OF INDOLALALKYL-PYRIDINIL-PYRIMIDINIL-PIPERAZINES, METHOD OF TREATMENT OR PREVENTION OF THE DEVELOPMENT OF VASCULAR HEADACHE AND PHARMACEUTICAL COMPOSITION
KR890012942A (en) 5-substituted ornithine derivatives
BR0011880A (en) Method for the treatment of co-morbid conditions associated with obesity, compound, product, use of a compound, and pharmaceutical composition
RU2001101445A (en) APPLICATION OF PEG-INTERFERON-ALPHA (PEG-IFN-ALPHA) AND RIBAVIRIN FOR THE TREATMENT OF CHRONIC HEPATITIS C
RU2004121687A (en) COMPOSITIONS CONTAINING EPOTHYLONS AND THEIR APPLICATION FOR TREATMENT OF A CARCINOID SYNDROME
RU2004124943A (en) COMBINATIONS INCLUDING EPOTHYLONS AND ANTI-METABOLITES
RU2008109649A (en) PEG-IFNα and Ribavirin for the Treatment of Hepatitis B Virus
AR025549A1 (en) MICOFELONATE MOFETIL IN ASSOCIATION WITH PEG-IFN-ALFA
RU2004116067A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING MACROLIDES
RU99118510A (en) COMPOSITION FOR THE TREATMENT OR PREVENTION OF PROSTATE CANCER
KR890701111A (en) Treatment of dyslipidemia in humans
RU96122371A (en) METHOD FOR TREATING ENDOGENOUS AND POSTOPERATIVE ANALYSIS
RU2002100065A (en) The use of verapamil and verapamil derivatives to obtain drugs with an action that inhibits β-glucuronidase in human tissue